Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Cancer of the Breast
Interventions: DRUG: Carboplatin|DRUG: Eribulin|DRUG: E7449
Sponsor: The University of Texas Health Science Center at San Antonio